Andexxa
Investigating Serious Complications Linked to Anticoagulant Reversal Drug
The lawyers at Cornell & Greene are currently investigating potential lawsuits for those who have suffered a serious blood clot, stroke, or other life-threatening complication after receiving Andexxa.
Andexxa was granted approval in 2018 on an accelerated basis by the United States Food and Drug Administration (FDA) for the reversal of life-threatening or uncontrolled bleeding in patients treated with anticoagulants Eliquis (apixaban) and Xarelto (rivaroxaban).
On December 18, 2025, the United States Food and Drug Administration (FDA) announced that it had received post-marketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa. The FDA determined that based on available data, “the serious risks, including the increase in thromboembolic events, are such that the FDA considers the risks of the product to outweigh its benefits.” AstraZeneca then removed Andexxa from the market.
If you or a loved one received Andexxa treatment and subsequently experienced any of the following complications you may be entitled to bring a case for compensation:
Blood Clots or Thrombotic Events
Deep Vein Thrombosis
Pulmonary Embolism
Ischemic Stroke
Transient Ischemic Attacks
Myocardial Infarction (Heart Attack)
Gastrointestinal Bleeding
Sudden Death
It is important that you explore your options and understand your legal rights.
Contact Us Today
If you or a loved one suffered a stroke, heart attack, clotting event, or other serious complication after receiving Andexxa, contact us for a free and confidential consultation.
See why Cornell & Greene, PLLC is unlike any other law firm.